UA107692C2 - Дизаміщені похідні піридину як протиракові препарати - Google Patents

Дизаміщені похідні піридину як протиракові препарати

Info

Publication number
UA107692C2
UA107692C2 UAA201209216A UAA201209216A UA107692C2 UA 107692 C2 UA107692 C2 UA 107692C2 UA A201209216 A UAA201209216 A UA A201209216A UA A201209216 A UAA201209216 A UA A201209216A UA 107692 C2 UA107692 C2 UA 107692C2
Authority
UA
Ukraine
Prior art keywords
phenylene
lower alkylene
optionally substituted
pyridine derivatives
lower alkyl
Prior art date
Application number
UAA201209216A
Other languages
English (en)
Russian (ru)
Inventor
Хідекі Такасу
Сігекадзу Фудзіта
Сінья Охтсука
Тосіюкі Хіросе
Йосуке Сато
Сатосі Ямада
Кейсуке Міядзіма
Кодзі Сакаі
Ютака Кодзіма
Казуо Секігуті
Ясуо Янагіхара
Такасі Судзукі
Хідео Танака
Кадзухіза Сугіяма
Міцухіро Окуно
Такумі Суміда
Original Assignee
Оцука Фармас'Ютікел Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Оцука Фармас'Ютікел Ко., Лтд. filed Critical Оцука Фармас'Ютікел Ко., Лтд.
Publication of UA107692C2 publication Critical patent/UA107692C2/uk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/69Two or more oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Даний винахід стосується нової сполуки, що має виняткову протипухлинну дію. Сполука за даним винаходом представлена наступною загальною формулою (1) EMBED ISISServer , (1) де R1 та R2 - це арил або тому подібні; А - це нижчий алкілен; кільце X - це вибірково заміщений арилен; Е - це зв'язок або нижчий алкенілен; кільце Y - вибірково заміщений гетероциклоалкілен, що містить один або більше атомів азоту, один з яких приєднаний до прилеглої карбонільної групи; G - це -NH-G2-, -N(нижчий алкіл)-G2-, -NH-CH2-G2-, -N[(нижчий алкіл)-СН2-G2- або -CH2-G2- [де G2 зв’язується з R2, G2-R2 - це зв'язок-R2, фенілен-G3-R2, фeнiлeн-G4-O-R2, фенілен-G5-NH-R2, фенілен-G6-N(нижчий алкіл)-R2 або хіноліндіїл-O-R2, фенілен зазначених груп, що містять фенілен, є вибірково заміщеними одним або більше замісниками; G3-R2 - це -О-нижчий алкілен-R2 або тому подібні; G4-O- - це нижчий алкілен-О- або тому подібні; G5 - нижчий алкілен; G6 - нижчий алкілен].
UAA201209216A 2010-01-29 2011-01-28 Дизаміщені похідні піридину як протиракові препарати UA107692C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29963110P 2010-01-29 2010-01-29
US35972910P 2010-06-29 2010-06-29
PCT/JP2011/052302 WO2011093524A1 (en) 2010-01-29 2011-01-28 Di - substituted pyridine derivatives as anticancers

Publications (1)

Publication Number Publication Date
UA107692C2 true UA107692C2 (uk) 2015-02-10

Family

ID=43797869

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201209216A UA107692C2 (uk) 2010-01-29 2011-01-28 Дизаміщені похідні піридину як протиракові препарати

Country Status (27)

Country Link
US (1) US8722663B2 (uk)
EP (1) EP2528897B9 (uk)
JP (1) JP5335932B2 (uk)
KR (1) KR101411030B1 (uk)
CN (1) CN102791690B (uk)
AR (1) AR080057A1 (uk)
AU (1) AU2011211306B2 (uk)
CA (1) CA2788073A1 (uk)
CO (1) CO6561817A2 (uk)
DK (1) DK2528897T3 (uk)
EA (1) EA026042B1 (uk)
ES (1) ES2521016T3 (uk)
HK (1) HK1178523A1 (uk)
HR (1) HRP20141190T1 (uk)
IL (1) IL221146A (uk)
MX (1) MX2012008391A (uk)
MY (1) MY160875A (uk)
NZ (1) NZ601794A (uk)
PL (1) PL2528897T3 (uk)
PT (1) PT2528897E (uk)
RS (1) RS53705B1 (uk)
SG (1) SG182663A1 (uk)
SI (1) SI2528897T1 (uk)
SM (1) SMT201500007B (uk)
TW (1) TWI404713B (uk)
UA (1) UA107692C2 (uk)
WO (1) WO2011093524A1 (uk)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013047223A (ja) * 2011-07-28 2013-03-07 Otsuka Pharmaceut Co Ltd 医薬
JP6433974B2 (ja) 2013-03-14 2018-12-05 トレロ ファーマシューティカルズ, インコーポレイテッド Jak2およびalk2阻害剤およびその使用方法
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
US9745319B2 (en) 2013-03-15 2017-08-29 Araxes Pharma Llc Irreversible covalent inhibitors of the GTPase K-Ras G12C
US10800751B2 (en) * 2013-08-23 2020-10-13 Virginia Commonwealth University Ester nitrates derivatives of aromatic aldehydes with multiple pharmalogic properties to treat sickle cell disease
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
JP2017528498A (ja) * 2014-09-25 2017-09-28 アラクセス ファーマ エルエルシー Kras g12c変異体タンパク質のインヒビター
US10011600B2 (en) 2014-09-25 2018-07-03 Araxes Pharma Llc Methods and compositions for inhibition of Ras
CN107849022A (zh) 2015-04-10 2018-03-27 亚瑞克西斯制药公司 取代的喹唑啉化合物和其使用方法
EP3283462B1 (en) 2015-04-15 2020-12-02 Araxes Pharma LLC Fused-tricyclic inhibitors of kras and methods of use thereof
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
EP3356347A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3356354A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US10975071B2 (en) 2015-09-28 2021-04-13 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3356351A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058728A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058792A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10689356B2 (en) 2015-09-28 2020-06-23 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017070256A2 (en) 2015-10-19 2017-04-27 Araxes Pharma Llc Method for screening inhibitors of ras
US10414757B2 (en) 2015-11-16 2019-09-17 Araxes Pharma Llc 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
US9988357B2 (en) 2015-12-09 2018-06-05 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
WO2017172979A1 (en) 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
CN110036010A (zh) 2016-09-29 2019-07-19 亚瑞克西斯制药公司 Kras g12c突变蛋白的抑制剂
CN110312711A (zh) 2016-10-07 2019-10-08 亚瑞克西斯制药公司 作为ras抑制剂的杂环化合物及其使用方法
US11279689B2 (en) 2017-01-26 2022-03-22 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
US11358959B2 (en) 2017-01-26 2022-06-14 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
EP3573970A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
WO2018140512A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
CN110382482A (zh) 2017-01-26 2019-10-25 亚瑞克西斯制药公司 稠合的杂-杂二环化合物及其使用方法
EP3630747A1 (en) 2017-05-25 2020-04-08 Araxes Pharma LLC Quinazoline derivatives as modulators of mutant kras, hras or nras
TW201906832A (zh) 2017-05-25 2019-02-16 美商亞瑞克西斯製藥公司 用於癌症治療之化合物及其使用方法
CN110869358A (zh) 2017-05-25 2020-03-06 亚瑞克西斯制药公司 Kras的共价抑制剂
KR20210003780A (ko) 2018-04-05 2021-01-12 스미토모 다이니폰 파마 온콜로지, 인크. Axl 키나제 억제제 및 그의 용도
JP2021530554A (ja) 2018-07-26 2021-11-11 スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド 異常なacvr1発現を伴う疾患を処置するための方法およびそこで使用するためのacvr1阻害剤
CN112812781B (zh) * 2021-01-21 2023-09-29 西安瑞联新材料股份有限公司 一种基于双哌嗪类苯并噁唑液晶化合物及其制备方法
CN116903587B (zh) * 2023-06-01 2024-03-22 三峡大学 一种角鲨烯环氧酶抑制剂及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63301880A (ja) * 1985-09-03 1988-12-08 Otsuka Pharmaceut Co Ltd 5−フルオロウラシル誘導体
AR015733A1 (es) * 1998-03-25 2001-05-16 Otsuka Pharma Co Ltd DERIVADO DE PIRIDINA, EL PRODUCTO Y LA COMPOSICIoN FARMACEUTICA QUE CONTIENE DICHO DERIVADO.
US6262088B1 (en) * 1998-11-19 2001-07-17 Berlex Laboratories, Inc. Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants
JP2001089412A (ja) * 1999-09-22 2001-04-03 Otsuka Pharmaceut Co Ltd ベンゼン誘導体またはその医薬的に許容される塩
JP2001089450A (ja) * 1999-09-22 2001-04-03 Otsuka Pharmaceut Co Ltd ピリジン誘導体含有医薬製剤
JP2002226429A (ja) * 2001-02-06 2002-08-14 Fuji Photo Film Co Ltd アクリル酸エステル化合物の製造方法
GB0224917D0 (en) * 2002-10-25 2002-12-04 Novartis Ag Organic compounds
CA2573223C (en) * 2004-08-06 2013-05-21 Otsuka Pharmaceutical Co., Ltd. Aromatic compound
SI1957073T1 (sl) * 2005-12-05 2014-08-29 Otsuka Pharmaceutical Co., Ltd. A Corporation Organized Under The Laws Of Japan Medicinsko zdravilo
JP5142513B2 (ja) * 2005-12-05 2013-02-13 大塚製薬株式会社 医薬
UA95978C2 (uk) 2006-10-02 2011-09-26 Оцука Фармас'Ютікел Ко., Лтд. Інгібітор активації stat3/5
WO2009005781A1 (en) 2007-07-02 2009-01-08 Dave Young System and method for clinical trial investigator meeting delivery and training, including dynamic media enrichment
TWI440638B (zh) * 2007-10-30 2014-06-11 Otsuka Pharma Co Ltd 雜環化合物及其藥學組成物
DE202009007345U1 (de) * 2009-05-22 2009-09-10 Schebo (R) . Biotech Ag Neue Pharmazeutika und Arzneimittelzubereitungen

Also Published As

Publication number Publication date
WO2011093524A9 (en) 2011-12-01
SMT201500007B (it) 2015-03-05
CA2788073A1 (en) 2011-08-04
EP2528897B1 (en) 2014-10-15
MY160875A (en) 2017-03-31
AU2011211306B2 (en) 2016-07-07
ES2521016T3 (es) 2014-11-12
DK2528897T3 (en) 2014-12-08
MX2012008391A (es) 2012-08-15
RS53705B1 (en) 2015-04-30
EP2528897B9 (en) 2015-09-09
EA201290720A1 (ru) 2013-02-28
NZ601794A (en) 2014-04-30
PT2528897E (pt) 2014-11-12
IL221146A (en) 2015-11-30
CN102791690B (zh) 2015-12-02
CN102791690A (zh) 2012-11-21
US20120283242A1 (en) 2012-11-08
SG182663A1 (en) 2012-08-30
JP2012525324A (ja) 2012-10-22
SI2528897T1 (sl) 2015-02-27
CO6561817A2 (es) 2012-11-15
US8722663B2 (en) 2014-05-13
EA026042B1 (ru) 2017-02-28
KR20120065268A (ko) 2012-06-20
HK1178523A1 (en) 2013-09-13
JP5335932B2 (ja) 2013-11-06
PL2528897T3 (pl) 2015-03-31
KR101411030B1 (ko) 2014-06-30
HRP20141190T1 (hr) 2015-01-30
AR080057A1 (es) 2012-03-07
TWI404713B (zh) 2013-08-11
WO2011093524A1 (en) 2011-08-04
EP2528897A1 (en) 2012-12-05
AU2011211306A1 (en) 2012-08-16
TW201136912A (en) 2011-11-01

Similar Documents

Publication Publication Date Title
UA107692C2 (uk) Дизаміщені похідні піридину як протиракові препарати
DE502008001409D1 (de) Bisamid-zinkbasen
CY1117157T1 (el) Υποκατεστημενο παραγωγο ισοκινολινης
MY148482A (en) Heterocyclic compound and pharmaceutical composition thereof
IN2014CN02838A (uk)
CR20130501A (es) Derivados novedosos de cefalosporinas y composiciones farmacéuticas de estos
UA89672C2 (en) Sulfonylamino(thio)carbonyl compounds
MY159870A (en) Piperazine compound capable of inhibiting prostaglandin d synthase
MY161134A (en) Piperazine compound having a pgds inhibitory effect
IN2014CN02843A (uk)
BR112014004523A2 (pt) composto e composição aromatizante
GB2470170A (en) Dithienothiophene derivatives
MX359363B (es) Dihidroetorfina y su preparacion.
WO2014184272A3 (en) Chemical compositions for targeting isocitrate dehydrogenase and for treating cancer
UA111950C2 (uk) Гетероциклічні сполуки для лікування або профілактики розладів, викликаних зниженою нейротрансмісією серотоніну, норепінефрину або допаміну
IN2012DN02755A (uk)
IN2014DN08653A (uk)
MX2013013262A (es) Derivados de ciclododecadienona como ingredientes de perfumado.
PH12014502108A1 (en) Polyamide compositions with improved optical properties
EA201390323A1 (ru) Производные 4-(метиламинофенокси)пиридин-3-илбензамида для лечения рака
AR085770A1 (es) Compuestos antibioticos derivados de homoeritromicina y composiciones farmaceuticas
SE1100784A1 (sv) Ny fosfatförening
MY176313A (en) Curable composition, curing product, and method for using curable composition
SA515360302B1 (ar) مركبات رباعي أكسا ثنائي فوسفا سبيرو
CY1115784T1 (el) Παραγωγα δι-υποκατεστημενης πυριδινης ως αντικαρκινικα